The prevalence and preventability of potentially relevant drug‐drug interactions in patients admitted for cardiovascular diseases: A cross‐sectional study

The aim was to describe the type and prevalence of potentially relevant drug‐drug interactions (pDDIs) in a population of patients admitted for cardiovascular diseases (CVD), and management strategies for reducing the occurrence of pDDIs.

[1]  Stewart E. Glaspole.  Stockley’s Drug Interactions , 2018 .

[2]  Peter Scarborough,et al.  Cardiovascular disease in Europe--epidemiological update 2015. , 2015, European heart journal.

[3]  B. Brock,et al.  Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review. , 2015, British journal of clinical pharmacology.

[4]  P. Bonnabry,et al.  Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. , 2015, European journal of internal medicine.

[5]  Bruce Guthrie,et al.  The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010 , 2015, BMC Medicine.

[6]  A. Mrhar,et al.  Drug-drug interaction software in clinical practice: a systematic review , 2015, European Journal of Clinical Pharmacology.

[7]  Michael A. Wittie,et al.  Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support , 2015, Drug Safety.

[8]  S. Mojal,et al.  Patient risk factors for developing a drug-related problem in a cardiology ward , 2014, Therapeutics and clinical risk management.

[9]  G. Onder,et al.  Understanding adverse drug reactions in older adults through drug-drug interactions. , 2014, European journal of internal medicine.

[10]  A. Mrhar,et al.  Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease , 2014, Archives of medical science : AMS.

[11]  H. Aljadhey,et al.  A systematic review of hospitalization resulting from medicine‐related problems in adult patients , 2014, British journal of clinical pharmacology.

[12]  Supinya Dechanont,et al.  Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta‐analysis , 2014, Pharmacoepidemiology and drug safety.

[13]  C. Tannenbaum,et al.  Understanding and preventing drug–drug and drug–gene interactions , 2014, Expert review of clinical pharmacology.

[14]  T. Egberts,et al.  Analysis of Potential Drug‐Drug Interactions in Medical Intensive Care Unit Patients , 2014, Pharmacotherapy.

[15]  Peter Scarborough,et al.  Cardiovascular disease in Europe: epidemiological update. , 2014, European heart journal.

[16]  Bernardo Santos-Ramos,et al.  Prevalence of drug interactions in hospital healthcare , 2012, International Journal of Clinical Pharmacy.

[17]  K. Ahmadi,et al.  Impact of pharmacists' intervention on identification and management of drug-drug interactions in an intensive care setting. , 2012, Singapore medical journal.

[18]  Ugo Moretti,et al.  Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions , 2012, Expert opinion on drug safety.

[19]  Lisa E Hines,et al.  Potentially harmful drug-drug interactions in the elderly: a review. , 2011, The American journal of geriatric pharmacotherapy.

[20]  J. E. Doormaal,et al.  Preventable and Non-Preventable Adverse Drug Events in Hospitalized Patients , 2011, Drug safety.

[21]  A. Rivkin,et al.  Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. , 2011, Journal of critical care.

[22]  Adriano Max Moreira Reis,et al.  Evaluation of three brands of drug interaction software for use in intensive care units , 2010, Pharmacy World & Science.

[23]  Walter E. Haefeli,et al.  Prevention of adverse drug reactions in intensive care patients by personal intervention based on an electronic clinical decision support system , 2010, Intensive Care Medicine.

[24]  G. Nichols,et al.  Medical care costs among patients with established cardiovascular disease. , 2009, The American journal of managed care.

[25]  C. Moura,et al.  Drug-drug interactions associated with length of stay and cost of hospitalization. , 2009, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[26]  S. Yusuf,et al.  Iatrogenic Adverse Events in the Coronary Care Unit , 2009, Circulation. Cardiovascular Quality and Outcomes.

[27]  G. Francis,et al.  Adverse drug reactions in patients with cardiovascular disease. , 2008, Current problems in cardiology.

[28]  S. Krähenbühl,et al.  Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. , 2008, European journal of internal medicine.

[29]  S. Krähenbühl,et al.  Evaluation of frequently used drug interaction screening programs , 2008, Pharmacy World & Science.

[30]  Ulrich Klotz,et al.  The clinical implications of ageing for rational drug therapy , 2008, European Journal of Clinical Pharmacology.

[31]  S. Haider,et al.  Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 - 2002. , 2007, International journal of clinical pharmacology and therapeutics.

[32]  Jeffrey L Schnipper,et al.  Clinical pharmacists and inpatient medical care: a systematic review. , 2006, Archives of internal medicine.

[33]  C. Marano,et al.  To err is human. Building a safer health system , 2005 .

[34]  T. Moger,et al.  The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals , 2004, European Journal of Clinical Pharmacology.

[35]  R. Schlienger,et al.  Potential drug–drug interactions in the medication of medical patients at hospital discharge , 2003, European Journal of Clinical Pharmacology.

[36]  A. Wall,et al.  Book ReviewTo Err is Human: building a safer health system Kohn L T Corrigan J M Donaldson M S Washington DC USA: Institute of Medicine/National Academy Press ISBN 0 309 06837 1 $34.95 , 2000 .

[37]  Peter Scarborough,et al.  Cardiovascular disease in Europe 2015: epidemiological update. , 2015, European heart journal.

[38]  Mitja Kos,et al.  Economic burden of cardiovascular diseases in Serbia. , 2014, Vojnosanitetski pregled.

[39]  Jochen Schuler,et al.  Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria , 2008, Wiener klinische Wochenschrift.

[40]  J. M. Cruciol-Souza,et al.  Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.